Quick Takeaways:
- Pelara has launched its first clinical trials in partnership with Openwater and SecureDX to bring Low-Intensity Focused Ultrasound (LIFU) to the veterinary market. The studies will initially evaluate the technology for chronic pain management in dogs, cats, and horses, generating the species-specific clinical evidence needed to support adoption across US veterinary practices.
- The program is focused on addressing chronic pain, one of the most common yet often undertreated conditions in companion animals. Unlike conventional therapies, LIFU uses targeted neuromodulation and localized musculoskeletal therapy without systemic drug exposure. The technology is designed to offer a non-invasive alternative to procedures such as nerve blocks and radiofrequency ablation.
- Through the collaboration, Openwater will contribute its LIFU technology, while SecureDX will provide diagnostic and data infrastructure to support clinical validation. The trials are intended to establish the safety and effectiveness of LIFU across multiple animal species and advance the commercialization of a precision, non-invasive treatment option for chronic pain in veterinary medicine.
Why It Matters?
Unlike drugs that carry safety concerns or diminishing effectiveness, LIFU aims to provide a non-invasive alternative to nerve blocks and radiofrequency ablation without systemic exposure, which could reduce reliance on medications and invasive procedures. For the market, generating species-specific safety and efficacy evidence is the key step that enables adoption across US practices, potentially opening a new precision therapy category for chronic pain and positioning LIFU as a complementary or alternative option alongside existing multimodal pain protocols.
Source: EIN Newswire
